Mitochondrial dysfunction is a key determinant of the rare disease lymphangioleiomyomatosis and provides a novel therapeutic target

Abdelwahab, E M M, Pal, S, Kvell, K, Sarosi, V, Bai, P, Rue, R, Krymskaya, V, McPhail, D, Porter, A & Pongracz, J E 2019, 'Mitochondrial dysfunction is a key determinant of the rare disease lymphangioleiomyomatosis and provides a novel therapeutic target', Oncogene, vol. 38, pp. 3093-3101. https://doi.org/10.1038/s41388-018-0625-1